BioSpace News Archive

GigaGen Inc. presented investigational new drug (IND)-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company’s oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

I-Mab today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.

Lunit is set to unveil seven significant abstracts at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place from November 26 to November 30 in Chicago.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023.

InflaRx N.V. (Nasdaq: IFRX) announced today that the first patient has been dosed in its Phase III study investigating the efficacy and safety of vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease characterized by destructive, painful cutaneous ulcers.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme’s ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target.

Meilleur Technologies, Inc. today announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023.

Opening today, the 2023 Milken Institute Future of Health Summit gathers hundreds of speakers and attendees who are inspired to share ideas and advance work around this year’s theme: “Closing the Gap: Better Health for More People.”